Loading the content... Loading depends on your connection speed!

Shopping Cart - $0.00

Cardiovascular Drugs Market Global Briefing 2017

Cardiovascular Drugs Market Global Briefing 2017

From $1,000.00

Including: Anti-hypertensive Drugs, Hypolipidemics, Anti Thrombotics, Other Drugs For Cardiovascular Diseases.
Covering: Merck & Co., Sanofi, Pfizer, Bristol-Myers Squibb Company, Novartis AG, Eli Lilly, Johnson & Johnson, AstraZeneca PLC, Abbott Laboratories Inc., Bayer AG


Clear selection
SKU: 2271. Categories: , .
Description

The major segments in the cardiovascular drugs market include anti-hypertensive drugs, hypolipidemics, anti thrombotics and other drugs for cardiovascular diseases.

Description

Cardiovascular Drugs Market Global Briefing from the Business Research Company covers market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies for this market.

The market characteristics section of the report defines and explains the market.

The market size section gives the cardiovascular drugs market revenues, covering both the historic growth of the market and forecasting the future.

Drivers and restraints looks at the external factors supporting and controlling the growth of the market.

Market segmentations break down the key sub sectors which make up the market. The regional breakdowns section gives the size of the market geographically.

Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in the last three years are identified.

The trends and strategies section highlights the likely future developments in the cardiovascular drugs market and suggests approaches.

Reasons to Purchase

• Get up to date information available on the cardiovascular drugs market globally.
• Identify growth segments and opportunities.
• Facilitate decision making on the basis of historic and forecast data and understand the drivers and restraints on the market.
• Develop strategies based on likely future developments.
• Gain a global perspective on the development of the market.

 

Scope

Markets Covered: Anti-hypertensive Drugs, Hypolipidemics, Anti Thrombotics, Other Drugs For Cardiovascular Diseases.
Companies Mentioned: Merck & Co., Sanofi, Pfizer, Bristol-Myers Squibb Company, Novartis AG, Eli Lilly, Johnson & Johnson, AstraZeneca PLC, Abbott Laboratories Inc., Bayer AG
Geographic scope: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa
Time series: Five years historic and forecast.
Data: Market value in $ billions.
Data segmentations: Regional breakdowns, market share of competitors, key sub segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Executive Summary
Cardiovascular drugs market covers the drugs used to treat conditions that affect the heart or blood vessels. These conditions include heart stroke, coronary artery diseases, valvular diseases, peripheral venous diseases, pericarditis, endocarditis, cardiac tumors, arteriosclerosis, and lymphatic diseases. Some of the major cardiovascular drugs include anti-hypertensive drugs such as calcium channel blockers and Angiotensin II receptor antagonists, and hypolipidemic drugs such as fibric acid derivatives and bile acid binding resins.

The global cardiovascular drugs market is expected to reach over $135 billion in 2020. The forecasted growth in this market can be attributed to the increase in aging population, increase in the prevalence of cardiovascular diseases and availability of more generic drugs that reduce the cost of treatment.

Novel Oral Anti-coagulants (NOACs) To Prevent Thrombosis - NOACs are gaining wider acceptance and are replacing traditionally used anti-coagulants such as Warfarin and Heparin. Anti-coagulants have long been used in prevention of thrombus formation in patients suffering with cardiovascular diseases. Use of NOACs makes it easier for patients to continue therapy post discharge as opposed to injections of Heparin and Warfarin which need medical assistance for administration xxviii. Some of the NOACs include Pradaxa (dabigatran etexilate) from Boehringer Ingelheim, Xarelto (rivaroxaban) from Janssen, and Eliquis (apixaban) from Bristol-Myers Squibb.
Table of Contents
Anti-infective Drugs Market Characteristics 5
Anti-infective Drugs Market Historic Growth 7
Anti-infective Drugs Market Forecast Growth 8
Anti-infective Drugs Market Segmentation 9
Global Anti-infective Drugs Market, Split By Segments, 2016, $ Billion 9
Antivirals 10
Antibiotics 10
Antifungals 10
Others (Antihelmethic, Antiprotozoal) 10
Global Anti-infective Drugs Market, Historic and Forecast, Split By Segments, 2012-2020 10
Anti-infective Drugs Market Geography Regional and Country Comparison 12
Global Anti-infective Drugs Market, Split By Regions, 2016 12
Global Anti-infective Drugs Market, Historic And Forecast Growth Rate, Split By Region, 2012-2020 14
Global Anti-infective Drugs Market, Split By Country, 2016 16
Global Anti-infective Drugs Market, Historic And Forecast Growth Rate, Split By Country, 2012-2020 18
Anti-infective Drugs Market Competitive Landscape 20
Gilead Sciences, Inc 21
Merck & Co. 21
Bristol-Myers Squibb Company 21
Johnson & Johnson 21
GlaxosmithKline Plc 21
AbbVie Inc. 21
Novartis AG 21
Pfizer Inc. 21
Otsuka Pharmaceutical Co., Ltd. 21
Bayer AG 21
Cardiovascular Drugs Market Characteristics 5
Cardiovascular Drugs Market Historic Growth 7
Cardiovascular Drugs Market Forecast Growth 8
Cardiovascular Drugs Market Segmentation 9
Global Cardiovascular Drugs Market, Split By Segments, 2016, $ Billion 9
Anti-hypertensive Drugs 10
Hypolipidemics 10
Anti Thrombotics 10
Global Cardiovascular Drugs Market, Historic and Forecast, Split By Segments, 2012-2020 11
Cardiovascular Drugs Market Geography Regional and Country Comparison 13
Global Cardiovascular Drugs Market, Split By Regions, 2016 13
Global Cardiovascular Drugs Market, Historic And Forecast Growth Rate, Split By Region, 2012-2020 15
Global Cardiovascular Drugs Market, Split By Country, 2016 17
Global Cardiovascular Drugs Market, Historic And Forecast Growth Rate, Split By Country, 2012-2020 19
Cardiovascular Drugs Market Competitive Landscape 21
Merck & Co. 22
Sanofi 22
AstraZeneca PLC 22
Novartis AG 22
Johnson & Johnson 22
Eli Lilly 22
Abbott Laboratories Inc. 22
Bayer AG 22
Pfizer 22
Bristol-Myers Squibb Company 22
Merck & Co. 23
Sanofi 23
Pfizer 24
Cardiovascular Drugs Market Key Mergers And Acquisitions 25
Teva Acquired Allergan’s Generic Business 25
Pfizer Acquired Hospira 25
AstraZeneca Acquired ZS Pharma 25
AstraZeneca Acquired Omthera Pharmaceuticals 25
Bristol-Myers Squibb Acquired Cardioxyl Pharmaceuticals 25
Cardiovascular Drugs Market Trends And Strategies 26
Novel Oral Anti-coagulants (NOACs) To Prevent Thrombosis 26
Approval Of New Drugs For Treatment Of Chronic Heart Failure 26
Personalized Medicine For Treatment Of Cardiovascular Disorders 26
Big Data 26
Appendix 28
NAICS Definitions Of Industry Covered In This Report 28
Definition Of Market Covered In This Report 28
Abbreviations 28
Currencies 28
Research Methodology 29
Research Inquiries 30
The Business Research Company 30

List of Figures
Figure 1: Global Cardiovascular Drugs Market, Historic Market Size, 2012-2016, $ Billion 7
Figure 2: Global Cardiovascular Drugs Market, Forecast Market Size, 2016 – 2020, $ Billion 8
Figure 3: Global Cardiovascular Drugs Market, Split By Segments, 2016, $ Billion 9
Figure 4: Global Cardiovascular Drugs Market, Historic and Forecast, Split By Segment, 2012 – 2020 11
Figure 5: Global Cardiovascular Drugs Market, Split By Region, 2016, $ Billion 13
Figure 6: Global Cardiovascular Drugs Market, Historic And Forecast Growth Rate, Split By Region, 2012-2020 15
Figure 7: Global Cardiovascular Drugs Market, Split By Country, 2016, $ Billion 17
Figure 8: Global Cardiovascular Drugs Market, Historic And Forecast Growth Rate, Split By Country, 2012-2020 19
Figure 9: Global Cardiovascular Drugs Market, Key Competitor Market Shares, 2016, Percentage (%) 21

List of Tables
Table 1: Global Cardiovascular Drugs Market, Historic Market Size, 2012-2016, $ Billion 7
Table 2: Global Cardiovascular Drugs Market, Forecast Market Size, 2016 – 2020, $ Billion 8
Table 3: Global Cardiovascular Drugs Market, Split By Segments, 2016, $ Billion 9
Table 4: Global Cardiovascular Drugs Market, Historic and Forecast, Split By Segment, 2012 – 2020 11
Table 5: Global Cardiovascular Drugs Market, Split By Region, 2016, $ Billion 14
Table 6: Global Cardiovascular Drugs Market, Historic And Forecast Growth Rate, Split By Region, 2012-2020 15
Table 7: Global Cardiovascular Drugs Market, Split By Country, 2016, $ Billion 17
Table 8: Global Cardiovascular Drugs Market, Historic And Forecast Growth Rate, Split By Country, 2012-2020 19
Table 9: Global Cardiovascular Drugs Market, Key Competitor Market Shares, 2016, Percentage (%) 22
Get Customized Report
Please fill in your details. Our team will get back to you